Spectrascience New Performance
| SCIEDelisted Stock | USD 1.42 0.00 0.00% |
The entity has a beta of 0.0253, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Spectrascience New's returns are expected to increase less than the market. However, during the bear market, the loss of holding Spectrascience New is expected to be smaller as well. Spectrascience New right now has a risk of 1.23%. Please validate Spectrascience New value at risk, kurtosis, and the relationship between the sortino ratio and semi variance , to decide if Spectrascience New will be following its existing price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Spectrascience New has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound forward indicators, Spectrascience New is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Spectrascience |
Spectrascience New Relative Risk vs. Return Landscape
If you would invest 142.00 in Spectrascience New on September 27, 2025 and sell it today you would earn a total of 0.00 from holding Spectrascience New or generate 0.0% return on investment over 90 days. Spectrascience New is currently generating 0.0072% in daily expected returns and assumes 1.2254% risk (volatility on return distribution) over the 90 days horizon. In different words, 10% of stocks are less volatile than Spectrascience, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Spectrascience New Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spectrascience New's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Spectrascience New, and traders can use it to determine the average amount a Spectrascience New's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0059
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SCIE |
Based on monthly moving average Spectrascience New is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Spectrascience New by adding Spectrascience New to a well-diversified portfolio.
Spectrascience New Fundamentals Growth
Spectrascience Stock prices reflect investors' perceptions of the future prospects and financial health of Spectrascience New, and Spectrascience New fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spectrascience Stock performance.
| Return On Asset | -0.92 | |||
| Current Valuation | 492.38 K | |||
| Shares Outstanding | 4.92 B | |||
| Price To Earning | (0.04) X | |||
| Price To Sales | 73.07 X | |||
| Revenue | 5.15 K | |||
| EBITDA | (1.99 M) | |||
| Cash And Equivalents | 27.88 K | |||
| Total Debt | 6.38 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.51 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 1.39 M | |||
| Retained Earnings | (53.97 M) | |||
| Current Asset | 479 K | |||
| Current Liabilities | 10.98 M | |||
About Spectrascience New Performance
By analyzing Spectrascience New's fundamental ratios, stakeholders can gain valuable insights into Spectrascience New's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Spectrascience New has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Spectrascience New has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California. Spectrascience operates under Medical Appliances Equipment classification in the United States and is traded on OTC Exchange. It employs 5 people.Things to note about Spectrascience New performance evaluation
Checking the ongoing alerts about Spectrascience New for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spectrascience New help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Spectrascience New is not yet fully synchronised with the market data | |
| Spectrascience New may become a speculative penny stock | |
| Spectrascience New has a very high chance of going through financial distress in the upcoming years | |
| Spectrascience New currently holds 6.38 M in liabilities. Spectrascience New has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Spectrascience New's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 5.15 K. Net Loss for the year was (4.47 M) with loss before overhead, payroll, taxes, and interest of (196.44 K). | |
| Spectrascience New currently holds about 27.88 K in cash with (1.51 M) of positive cash flow from operations. |
- Analyzing Spectrascience New's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spectrascience New's stock is overvalued or undervalued compared to its peers.
- Examining Spectrascience New's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Spectrascience New's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spectrascience New's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Spectrascience New's stock. These opinions can provide insight into Spectrascience New's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Spectrascience Stock
If you are still planning to invest in Spectrascience New check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrascience New's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |